User:RelentlessRecusant/SB-277011

SB-277011, IUPAC name trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide, is a specific small-molecule chemical inhibitor of dopamine receptor 3 (D3). It was originally synthesized, optimized, and characterized by Stemp et. al in 2000 at GlaxoSmithKline in Harlow, United Kingdom.